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Abstract
Patients undergoing cochlear implantation could benefit from a simultaneous application of
drugs into the ear, helping preserve residual low-frequency hearing and afferent nerve fiber
populations. One way to apply drugs is to incorporate a cannula into the implant, through
which drug solution is driven. For such an approach, perilymph concentrations achieved
and the distribution in the ear over time have not previously been documented. We used
FITC-labeled dextran as a marker, delivering it into perilymph of guinea pigs at 10 or 100 nL/
min though a cannula incorporated into a cochlear implant with the outlet in the mid basal
turn. After injections of varying duration (2 hours, 1 day or 7 days) perilymph was collected
from the cochlear apex using a sequential sampling technique, allowing dextran levels and
gradients along scala tympani to be quantified. Data were interpreted quantitatively using
computer simulations of the experiments. For injections of 2 hours duration, dextran levels
were critically influenced by the presence or absence of fluid leakage at the cochleostomy
site. When the cochleostomy was fluid-tight, substantially higher perilymph levels were
achieved at the injection site, with concentration declining along scala tympani towards the
apex. Contrary to expectations, large dextran gradients along scala tympani persisted after
24 hours of sustained injection and were still present in some animals after 7 days injection.
Functional changes associated with implantation and dextran delivery, and the histological
state of the implant and cannula were also documented. The persistent longitudinal gradi-
ents of dextan along the ear were not readily explained by computer simulations of the
experiments based on prior pharmacokinetic data. One explanation is that inner ear phar-
macokinetics are altered in the period after cochlear implantation, possibly by a permeabili-
zation of the blood-labyrinth barrier as part of the immune response to the implant.
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Introduction
Cochlear implants have been a highly successful therapy for patients with severe or profound
deafness. Nevertheless, as they are an implanted “foreign body” in the ear, improvements of
performance can potentially be achieved using drug or gene therapies in combination with
implantation. Such therapies have potential value to preserve residual low-frequency hearing
[1–7], maintain neural density [8–12], prevent endolymphatic hydrops [13], reduce fibrosis
and ossification around the implant [14–15], and to maintain low electrode impedances which
provide better speech discrimination [16–18]
Protocols for drug delivery in conjunction with cochlear implantation, and their influence
on drug levels in the implanted cochlea, have not been studied in detail. In practice, many vari-
ables associated with drug delivery vary from study to study. The timing of drug application
includes treatments before [1,2,14,19], at time of [20–21], or after cochlear implantation [22].
The route of delivery can include both systemic and local applications to the ear. Local applica-
tions include intratympanic injections, injections directly into perilymph through a cannula in
the implant [23–24], or eluted into perilymph from the body of the implant [15,25].
Drug dosing has been largely empirically-based and only few studies have measured drug
levels achieved in perilymph [26]. A greater understanding of perilymph pharmacokinetics for
drugs delivered directly into perilymph would allow delivery protocols to be optimized to
ensure efficacious, non-toxic dosing. While there have been numerous pharmacokinetic stud-
ies in animals and humans with intratympanic / round window niche applications, there are
only few with intracochlear applications, either by drug injection, elution from an implant
[26], or from particles placed at the time of delivery [27].
In the present study, we have measured both the drug amount and drug distribution along
scala tympani (ST) following implantation with an electrode/cannula combination. The tech-
nique of “sequential perilymph sampling” was used to measure drug gradients in the ear. In
this technique, 10 individual fluid samples were collected following perforation of the cochlear
apex and each analyzed independently, allowing drug concentration gradients along ST to be
quantified. Drug distribution and auditory function were measured at 2 hours after implanta-
tion in acute experiments, and at 24 hours or 7 days after implantation in recovery experi-
ments. Outcome predictions and interpretation of data were performed with a computer
program that simulates drug movements in the inner ear fluids.
Materials and methods
Animals
The study utilized 45 pigmented, NIH-strain guinea pigs weighing 400–600 g. Experiments
were conducted in accordance with policies of the United States Department of Agriculture,
the National Institutes of Health guidelines for the handling and use of laboratory animals,
and under protocol 20140083 approved by the Institutional Animal Care and Use Committee
of Washington University.
Cochlear implantation with cannula and pump
The cochlear implant used in this study is shown in Fig 1. They were HL8 devices, manufac-
tured and provided for our use by Cochlear Corp. They consisted of an 8-electrode array scaled
in size to fit a guinea pig cochlea, adapted from a design by Shepherd & Xu (2002). They incor-
porated a 0.102 mm ID polyimide cannula, which exited the implant after the second electrode.
Cochlear implantation with continuous delivery of solution for 24 hours or 7 days was per-
formed as a sterile, recovery procedure. Injection solution was made by adding FITC-dextran
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(10 mM) to sterile minimum essential medium (MEM α; 51200–038; no phenol red; Fisher
Scientific: www.thermofisher.com) followed by filtration to ensure sterility. The solution was
delivered from an iPRECIO SMP-300 peristaltic pump, controlled by an internal microproces-
sor, programmed to inject at a constant rate of 10 nl/min (0.6 μL/hr). Although the injection
medium was slightly (~ 3%) hypertonic, the injection rate is so low (~0.2% of ST volume per
minute) that any disturbance would be highly localized near the cannula outlet.
FITC-dextran did not stain the silicone tubing of the pump or the silicone of the implant,
indicating there was no non-specific adsorption of the FITC-dextran to the delivery compo-
nents of the system.
The polyimide cannula was interfaced to the 0.55 mm ID silicone tubing of the pump with
a 10-mm length of 21G stainless tubing. The coupler was slipped over the polyimide and thin
cyanoacrylate glue (Permabond 101) was applied to fill the space between the polyimide and
the stainless tubing, without allowing it to enter the lumen of the polyimide. After the glue had
hardened, the polyimide tubing extending beyond the coupler was removed with a sharp blade
and the coupler was sutured to the implant to provide strain relief for the polyimide. At the
time of surgery, the stainless coupler was inserted into the silicone tubing of the pump, displac-
ing enough volume to completely fill the polyimide cannula.
For cochlear implantation as a recovery procedure, animals were initially administered
0.05mg/kg buprenorphine as an analgesic, then anesthetized with 0.8 to 1.2% isofluorane in
oxygen, first in a Plexiglas chamber and then delivered through a nosecone. Heart rate and O2
saturation were monitored with a pulse oximeter (Surgivet, Waukesha, WI). Lidocaine (0.25–
0.5 ml, 2%) was injected at the surgical site. A post-auricular incision was made, followed by
opening the lateral bulla to expose the basal turn of the cochlea. A cochleostomy was drilled
into ST with a slowly rotating 0.375 mm fluted carbide burr, avoiding the round window
membrane. The implant and cannula system was slowly inserted into the cochlea until the sili-
cone marker band fitted snugly into the cochleostomy, in most cases forming a fluid-tight seal.
A subcutaneous pocket was made, extending from the post-auricular incision up between the
scapulae. The pump was inserted into the pocket until it was located on the back of the animal.
The lateral bulla was dried and closed with multiple layers of dental cement, orientating the
implant and cannula tubing dorsally towards the pump. Muscles and skin were sutured closed.
Fig 1. The implant-cannula-pump system ready for implantation. The pump reservoir was filled with 10 mM FITC-dextran solution in a bicarbonate-
buffered artificial perilymph. The pump was coupled to the polyimide cannula of the implant with a 10 mm length of 21G stainless tubing, fixed to the
polyimide tubing with cyanoacrylate. The stainless coupler was sutured to the implant to limit strain on the polyimide tubing.
https://doi.org/10.1371/journal.pone.0183374.g001
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Animals were given subcutaneous lactated Ringer’s solution and 0.05 mg/kg buprenorphine
every 8–12 hours.
Animal preparation for short injections and perilymph sampling
All animals underwent a terminal procedure in which inner ear fluids were sampled for analy-
sis and in some, auditory function was also tested. Animals were anesthetized with 100 mg/kg
sodium thiobutabarbital (Inactin, Sigma, St Louis, MO) and maintained on 0.8 to 1.2% iso-
fluorane in oxygen using a mechanical ventilator combined with a tracheal cannula. A 5%
end-tidal CO2 level was maintained, monitored with a CapnoTrue AMP (Bluepoint Medical,
The Netherlands), through adjustment of the ventilator’s tidal volume. Heart rate and oxygen
saturation were monitored with a (Surgivet. Waukesha, WI) pulse-oximeter. Body tempera-
ture was maintained at 38˚C with a thermistor-controlled heating blanket. At the end of the
procedure, animals were sacrificed while under deep anesthesia by either intravenous injection
of 3M KCl or by exsanguination during the removal of temporal bones.
In those animals that had not been injected by the recovery procedure described above, a
single, 2 hr injection was performed. In these experiments, injection rates of either 10 nL/min
or 100 nL/min were used, performed with an iPRECIO SMP-300 pump (10 nL/min; 130 μL
reservoir, available rates 0–167 nl/min), an iPRECIO SMP-200 pump (100 nL/min; 900 μL res-
ervoir, available rates 16–500 nl/min) or with a World Precision Instruments Ultrapump
(motor driven syringe pump) at 10nL/min or 100 nL/min. The injected solution was 1 or 10
mM FITC-dextran (fluorescent dextran, FW ~4000, Sigma-Aldrich, St. Louis MO) in a back-
ground artificial perilymph solution containing NaCl (125 mM), KCl (3.5 mM), NaHCO3 (25
mM), CaCl2 (1.3 mM), MgCl2 (1.2 mM), NaH2PO4 (0.75 mM), and dextrose (5 mM).
Sequential sampling from the cochlear apex
Gradients of dextran along the perilymphatic spaces were measured directly from multiple
samples obtained by a technique called “sequential sampling” ([28,29]. When the apex is perfo-
rated, perilymph is driven out by cerebrospinal fluid (CSF) entering the basal turn of ST
through the cochlear aqueduct, pushing perilymph in an apical direction along the scala. The
first sample collected originates from perilymph near the apex and each following sample from
perilymph that originated from a scala location progressively closer to the base. After all ST
perilymph has been pushed out, subsequent samples contain CSF that has passed through the
scala. Samples collected in this manner allow drug gradients along the length of ST to be quan-
tified. Perilymph was collected from the cochlear apex as a series of individual 1 μL samples
collected over a 10–20 min period. To prepare the cochlea for sample collection the middle ear
mucosa overlying the cochlear apex was first removed and the bone was allowed to dry. A thin
layer of cyanoacrylate glue (Permabond 101; Permabond, Pottstown, PA) was applied to the
dry bone, followed by layers of two-part silicone adhesive (Kwik-Cast, World Precision Instru-
ments, Sarasota, FL), built up at the edges to form a hydrophobic cup. At the time of sampling
a 30–40 μm fenestration was made at the apex through the adhesives using a 30˚ House stapes
pick (N1705 80, Bausch and Lomb Inc.). Clear, uncontaminated fluid flows from the fenestra-
tion, accumulating on the hydrophobic surface, as shown in Fig 2A. Fluid was collected with
hand-held, blunt tipped capillary tubes (VWR 53432–706; VWR Radnor, PA), each marked
for a nominal volume of 1 μL and taking 1–2 min to collect. The length of each sample in its
capillary tube was measured with a calibrated dissecting microscope, from which the exact
sample volume was established. Ten individual samples were collected in this manner. The
approximate spatial origins of the first four fluid samples, based on the cross-sectional area of
the guinea pig ST and corrected for the area occupied by the cochlear implant, are shown in
Pharmacokinetics of marker applied through a cochlear implant
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Fig 2B. Data derived from direct measurement of sample concentrations are shown as solid
symbols in the figures.
Sample handling and analysis
Samples from the ear and samples of the injection medium were expelled from the collection
capillary into 150 μL of diluent (phosphate-buffered saline with sodium azide preservative
(Santa Cruz Biotechnology, Inc; www.scbt.com). Injection solution was also used to make a
dilution series, by adding 300 μL of solution to 2.7 ml PBS diluent (10x dilution), repeated 8
times. Samples were loaded into a disposable 96 well plate and read in a SpectraMax i3 plate
reader with SoftMax Pro 6.4 software with parameters optimized for FITC-dextran (495 nm
excitation, 15 nm bandwidth and 535 nm emission, 25 nm bandwidth). A sigmoid curve (Hill
function) was fitted to the dilution series measurements and was used to convert fluorescence
brightness to concentration.
Data interpretation through simulations of the experiments
Predictions and quantitative interpretation of measurements were provided by our established
simulation program, available for download at oto.wustl.edu/saltlab. The simulator calculates
solute distribution based only on established physical processes, such as diffusion, volume
flow, elimination and exchange with adjacent compartments. Simulations take into account
the dimensions all the fluid and tissue spaces of the guinea pig cochlea and vestibular system.
The cross-sectional area of each compartment is defined with 0.1 mm resolution along its
length, derived from 3D reconstructions of orthogonal plane fluorescence optical sectioning
(OPFOS) images for 16 compartments of the ear. In this application, the simulations corrected
the ST area with distance based on the space occupied by the implant. ST kinetics are also cor-
rected for the volume change caused by the implant, as a specific transport process acting into
a smaller fluid volume results in faster kinetics. The kinetic parameters used for FITC-dextran
distribution in the cochlea were based on those derived from analysis of 10 different FITC-
Fig 2. Perilymph sample origins. (A) Exposed guinea pig cochlea with a cochlear implant inserted into the basal turn of scala tympani and with
the apex prepared for sequential fluid sampling. The green substance surrounding the apex is silicone adhesive (see methods). The apex has been
perforated and fluid efflux is accumulating on the hydrophobic surface, which can be collected with minimal contamination. (B) Calculated spatial
origins for the first four 1 μL perilymph samples collected from the apex, based on the measured cross-sectional area (CSA) of the perilymphatic
compartments. The first sample includes the apical portion of scala vestibuli where the samples are collected. Later samples take into account the
unavailable volume occupied by the cochlear implant in the 1.3 to 8.3 mm region of scala tympani (ST). Fluid samples are also influenced by solute
exchange with adjacent compartments as they travel up the cochlea (not represented in this figure).
https://doi.org/10.1371/journal.pone.0183374.g002
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dextran application and sampling conditions [30]. Data derived from simulations are shown
as open symbols in the Figures.
Functional measurements
Sound stimulation and response collection were performed with Tucker-Davis system 3 hard-
ware, controlled by a custom-written data collection program. Sounds were delivered in a
closed system through a hollow ear bar, placed in the external canal after it had been
transected.
Cochlear action potential (CAP) responses were measured from a ball electrode placed on
the cochlear apex. The apex was chosen to avoid local influences of the implant, such as addi-
tional fluid accumulation at the RW niche due to fluid leakage at the cochleostomy. CAP
responses were collected in response to 20 alternating tone burst stimuli. For frequencies > 4
kHz we used a 0.5 ms linear rise-time and for frequencies < 4 kHz a linear, 2 cycle rise time
(i.e. 4 ms at 500 Hz). Responses were low-pass filtered with a 2-kHz cutoff for stimuli > 2 kHz
and with the cutoff at the stimulus frequency for responses to stimuli below 2 kHz. The filter-
ing was intended to attenuate cochlear microphonics and more importantly auditory nerve
overlapped waveform (ANOW) response components [31] that occur at twice the stimulus fre-
quency. For responses to stimuli of 3 kHz and above, CAP was measured as the amplitude of
the N1-P1 component. For CAP responses to stimuli of less than 3 kHz, AP transitioned into a
slow negative wave which was measured as the baseline-N1 amplitude. CAP thresholds were
established using an automated procedure with 10 μV criterion, increasing sound level in 5 dB
steps until an above-criterion response was detected, then decreasing in 5 dB steps. With these
procedures to minimize CM and ANOW contributions at low frequency we were able to
record AP thresholds down to 200 Hz. Typically, cochlear sensitivity was measured from 200
Hz to 22 kHz in ¼ -octave steps.
Acoustic emission (2f1-f2) thresholds were measured using an Etymotic ER10C system
incorporated into the hollow ear bar. F2 was set to a frequency 1.2x f1 and to a level 10 dB
below f1. Stimulus levels were adjusted in 5 dB steps until the 2f1-f2 emission was 10 dB above
the unstimulated noise floor. Emission thresholds were collected from 500 Hz to 8 kHz in
¼-octave steps.
Histological assessment
The ear of animals undergoing 24 hr and 7 day injections were fixed for histological assess-
ment. The implant was left in place and was cut off with fine scissors just outside the cochlea at
the cochleostomy. The ear was isolated, the round window perforated and the stapes dislocated
and was fixed by immersion in 4% paraformaldehyde + 0.1% glutaraldehyde in phosphate
buffered saline. Ears were subsequently either microdissected under water or dehydrated in
ethanol and embedded in Epotek epoxy resin (www.epotek.com). Resin embedded specimens
were surface-ground and surface-stained with eosin Y and toluidine blue to reveal internal
structures in relation to the implant.
Statistical significance was assessed by Sigmaplot v13 software (Systat: systatsoftware.com)
Results
Two hour injection studies
The predicted distribution of FITC-dextran following local injections into the basal turn of ST
was calculated, as shown in Fig 3. The simulation parameters were based on extensive prior
studies in which FITC-dextran marker was injected into perilymph and sampled with 10
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different protocols. Simulation parameters were established that fitted the measured data from
all 10 protocols [30]. In those experiments, dextran was injected from glass pipettes sealed into
the bony wall of the otic capsule, with perilymph sampling occurring up to two hours after-
wards. Fig 3 shows the calculated concentrations two injection rates (100 nL/min and 10 nL/
min). The distribution of dextran along the length of ST (Fig 3; upper row) and the calculated
sample concentrations for 10 x 1 μL samples collected sequentially from the cochlear apex (Fig
3; lower row) are shown for high rate, low concentration (100 nL/min, 1 mM) and for low
rate, high concentration (10 nL/min, 10 mM) injections from the cochlear implant of varying
durations from 1 to 12 hours. The concentration distribution along ST is initially dominated
by the basal turn application, with concentration declining markedly with distance towards
the apex. With time, the apical concentration is predicted to rise as the dextran spreads both
by diffusion and under the influence of a small apically directed flow (~30 nL/min) shown to
Fig 3. Calculated gradients and sample concentrations. Calculated gradients along ST (upper row) and corresponding predicted sample
concentrations (lower row) for FITC-dextran injections into ST for durations of 1 to 12 hours. The left column shows the results of 1 mM dextran
injected at 100 nL/ min, and the right column shows the results of 10 mM dextran injected at 10 nl/min, with both injections occurring at 2.8 mm
from the base of ST. The calculations use simulator parameters based on analysis of FITC-dextran data for 10 different injection-sampling
conditions [30], summarized in the text. Initially, a large gradient for dextran along ST is expected (red and blue curves in A and B) but the
gradient is expected to decline as injection is prolonged and to disappear after 8–12 hours injection. The same is expected with the lower
injection rate, but in this case the basal region of ST is not filled as effectively with dextran (B vs. A), so the peak of the sample curve occurs at
sample 3 with 10 nL/min injection (D), rather than sample 4 with 100 nL/min injection (C).
https://doi.org/10.1371/journal.pone.0183374.g003
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exist in the normal, sealed cochlea. The corresponding samples that would result from the
drug distributions in Fig 3A & 3B are given in Fig 3C & 3D respectively. For both injection
conditions the first sample, originating from apical perilymph, is initially low but increases
over time as dextran spreads apically with time along the cochlea. Although samples 4–5 origi-
nate from perilymph at the base of ST, they pass along the length of ST, interacting with adja-
cent tissue compartments, so the concentrations of samples 4 and 5 are lower when there is
lower concentration in apical regions. The simulations incorporate and take into account the
inter-compartment interactions during delivery and sampling. The simulations predict that
substantial gradients of dextran along the cochlea will occur at early times (such as 1 or 2
hours) after injection starts. The calculated ratio of sample 3 to sample 1 (hereafter described
as the 3:1 ratio) after 2 hrs injection was 3.10 at 100 nL/min injection rate and 3.62 at 10 nL/
min injection rate. Previous studies have shown that dextran is retained well in perilymph (i.e.
elimination rate is low), so the dextran would be expected to distribute to the apical regions
within 8–12 hrs of injection, with a 3:1 ratio then approaching 1.
The results of perilymph sampling experiments following 2 hr injections at 100 nL/min are
shown in Fig 4. Based on years of experience trying to seal measurement and injection pipettes
into perilymph, we initially expected it to be impossible to seal something the size of the
cochlear implant effectively into the otic capsule. As low rates of leakage would be difficult to
measure, we classified the amount of leakage based on the state of the middle ear at the end of
the two-hour injection. If there was fluid leakage at the cochleostomy, fluid typically leaked at
about 1 μL/min, which amounted to 120 μL over the 2 hr period. Such a volume would almost
fill the bulla so it would be easily recognized. Based on this criterion we found that packing
Fig 4. Measured dextran concentrations in perilymph samples. Dextran concentrations were measured for sequential fluid samples collected
from the apex of implanted animals in which the cochleostomy was leaking during injection (A) or in which there was no detectable leak from the
cochleostomy during the 2 hr injection period (B). Injections were performed at 100 nL/min either with a WPI Ultrapump (solid circles) or with iPRECIO
SMP-200 pumps (solid triangles). Group average curves are shown in black. With leakage at the cochleostomy, the peak of the average marker
concentration occurred in the 3rd sample and averaged 271 μM (SD 103, n = 7) while with no leakage at the cochleostomy the peak of the average
marker concentration occurred in the 4th sample and averaged 529 μM (SD 138, n = 4). The predicted curve (from Fig 3C; 2 hr) is shown for comparison
(gray diamonds). Measured concentrations were typically lower than predicted.
https://doi.org/10.1371/journal.pone.0183374.g004
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around the implant with fascia and/or bone dust was not able to produce a fluid-tight seal. We
subsequently discovered that when the cochleostomy was carefully drilled with a slowly-rotat-
ing burr, without entering the scala, it could be precisely sized so that the implant would fit
tightly. Furthermore, as the implant incorporated a raised silicone band as an insertion
marker, we found it was possible to insert the compressible insertion band snugly into the
cochleostomy, to an extent that a complete fluid seal was achieved. Experiments were subse-
quently classified more rigorously based on whether any fluid accumulation occurred in the
RW niche during the 2 hr experiment. Those in which we found no fluid in the niche were
classified as having a sealed cochleostomy. If any fluid was present after 2 hrs, the experiment
was classified as having a leaking cochleostomy. In practice, intermediate, low rates of leakage
were not found to occur. Either the cochleostomy leaked profusely, or it was sealed. The con-
centration of FITC-dextran in perilymph after 2 hrs injection was highly dependent on
whether the cochleostomy leaked or not, as shown in Fig 4. When there was leakage at the
cochleostomy the peak of the group mean sample concentration curve (Fig 4A; black curve)
occurred in sample 3 and averaged 271 μM (SD 103, n = 7). In comparison, with no leakage at
the cochleostomy the peak of the average marker concentration was significantly higher
(2-way ANOVA, Bonferroni p<0.001). The peak of the group mean sample curve occurred in
sample 4 (Fig 4B; black curve) and averaged 529 μM (SD 138, n = 4).
Even in the absence of leakage at the cochleostomy, most of the measured perilymph con-
centration curves were below predicted concentrations (shown in Fig 4B as the gray dotted
line, taken from Fig 3C, 2 hr curve). Thus, in the injected, implanted ear we generally found
lower perilymph concentrations of FITC-dextran compared to injections from glass pipettes
sealed into the perilymphatic space as performed in our prior study and on which the predic-
tions were based. In each of the concentration curves in Fig 4B, the measured concentration of
sample 1 was notably lower than that predicted by simulation, with calculated 3:1 ratios of the
measurements averaging 22.0 (SD 8.8, n = 4).
24 hour and 7 day injection studies
For prolonged FITC-dextran injections through the implant we chose to use the iPRECIO
SMP-300 pump which has a 130 μL reservoir. At an injection rate of 10 nL/min, this pump
will run for 9 days without re-fill. The results of sampling perilymph in animals after 2 hr, 24
hr and 7 day injections of FITC-dextran at 10 nL/min are summarized in Fig 5. For 2 hr injec-
tions (Fig 5A) the peak concentration occurred in sample 3, consistent with the simulator pre-
diction (Gray curve shows prediction from Fig 3D, 2 hr). In 3 animals, the peak was close to
the predicted concentration, but was lower in the other 2, so the mean curve (black) was lower
than the prediction. In similarity with the 100 nL/min injections, measured sample 1 concen-
tration was lower than the simulator prediction. The 3:1 ratio for the measured 2 hr curves
averaged 57.4, but was highly variable (SD 64.7, n = 5).
After 24 hr injections (Fig 5B), perilymph concentration was significantly higher (2-way
ANOVA, Bonferroni t-test, p<0.001), in keeping with the prediction. Nevertheless, substantial
gradients remained, as demonstrated by the 3:1 ratio for the measured 24 hr curves which still
averaged 4.40 (SD 1.4, n = 4). In one animal, an abnormally late peak was observed at sample
6.
Seven-day injection experiments were found to be more challenging. The polyimide can-
nula was found to have broken where it had been cemented into the bulla in 3 animals and the
pump failed in 1 animal. Successful injections and sampling were achieved in 3 of the 7 ani-
mals (Fig 5C). In the successfully-injected animals the highest sample of the average was sam-
ple 2. Perilymph concentrations after 7 day injections were significantly lower than those with
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24 hr injections (2-way ANOVA, Bonferroni t-test, p<0.001) but sample 1 was notably higher
than both groups with shorter injection durations. The mean 3:1 ratio was 1.54 (SD 0.54, n =
3). The mean curves for the 3 groups are overlaid in Fig 6A. A progressive increase of apical
perilymph concentration (sample 1) as injection time increases is apparent. Fig 6B shows the
measured variation of sample 3:1 ratio over time for individual experiments. A regression line
fitted to the points indicates that the time for the base-apex longitudinal gradient to subside
(to a 3:1 ratio of 1) would require 11 days of injection. For comparison, the predicted decline
in ratio, calculated from the curves in Fig 3D is shown as the dotted red line. The experimental
data therefore show that achieving uniform distribution of drug along the length of ST with
injection through an implanted cannula is even more difficult than we had anticipated.
Interpretation of 24 hr injection data through simulations
Perilymph measurements following prolonged injections through the implant can be used to
improve the accuracy of simulations that were previously based on limited-duration (2–3 hr)
studies with injections through glass pipettes that were sealed into the otic capsule. We were
initially interested in whether simulations could better fit the new data through parameter
adjustments or whether fundamental changes in the underlying processes of the simulations
were required.
An important parameter affecting drug gradients along the scalae is the process of elimina-
tion, which represents the loss of solute from perilymph in an irreversible manner, assumed to
be directed to blood. For local drug applications, longitudinal gradients along ST become
larger as elimination increases. If elimination occurs faster than the drug diffuses, the drug
may never reach the cochlear apex in appreciable concentration and longitudinal gradients
will remain high over time. Although previous studies indicated dextran elimination was slow,
we considered whether a higher elimination rate could account for the results. The influence
of elimination on calculated sample curves is shown in Fig 7. Fig 7A shows the calculated
samples for 24 hr applications, with their corresponding sample 3:1 ratios shown in Fig 7B.
Increasing elimination from ST increased the longitudinal gradient at 24 hours, as measured
by the increase of the sample 3:1 ratio. With elimination half time at about 30 min the 3:1 ratio
Fig 5. Dextran measurements at three time-points. Perilymph concentration of FITC-dextran in sequential samples collected from the apex after 2 hr
(A), 24 hr (B) or 7 day (C) injections at 10 nL/min. Colored curves are individual experiments, black curves are the group mean and gray curves with open
symbols are the simulator predictions. The mean 2 hr curve is lower, but similar to the predicted curve, with sample 3 having the highest concentration.
Contrary to the prediction, dextran gradients were found to be still present even after 24 hours of injection, as seen in the low concentration found in
sample 1 of all animals relative to sample 3. Even after 7 days, gradients still remained in some animals.
https://doi.org/10.1371/journal.pone.0183374.g005
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was comparable to that of the average measured curve. However, elimination at this rate
caused all calculated concentrations to be reduced, with sample 3 only at ~29% of that mea-
sured. Changing elimination rate cannot therefore simultaneously explain both the magnitude
of the longitudinal gradient and the amount of dextran measured in samples after 24 hr
injections.
A second factor influencing drug gradients along ST is the ongoing slow flow of CSF enter-
ing ST at the cochlear aqueduct. In prior studies, we found this was the primary cause of dex-
tran decline in the basal turn of ST following injections, with an estimated CSF influx of
around 30 nL/min accounting for the decline. Volume flow along ST towards the apex helps
move dextran apically, thereby reducing the gradient. We therefore considered whether a
lower volume flow rate could result in larger gradients for longer injections. The influence of
varying flow rate on sample curves and the 3:1 ratio are shown in Fig 7C and 7D respectively.
Reducing flow towards the apex does increase the 3:1 ratio, and including a small basally-
directed flow in ST brings the calculated ratio close to that measured. However, changing flow
in ST also changes the shape of the sample curve, specifically increasing the concentration of
samples from basal regions (samples 4 and 5) as the influx of CSF is reduced. Reducing CSF
influx and increasing movement from the injection site towards the aqueduct both act to
increase dextran concentration in the most basal part of ST. The calculations show that it is
not possible to account for the measured drug gradients and concentration of samples origi-
nating from the basal turn by varying flow rate. Simple parameter modifications of the simula-
tions apparently cannot account for the measured dextran distributions after 2 hr and 24 hr
injections.
By making substantial changes to some of the processes in the simulations we were able to
approximate both the 2hr and 24hr sample data with a single set of parameters, as shown in
Fig 8. In these calculations, we added base-apex gradients in both the rate of elimination and
in the rate of longitudinal volume flow. Elimination was set to be faster from the apex (half
Fig 6. Perilymph measurements at 3 time points compared. (A) Group mean curves for the three injection durations of 2hr, 24 hr or 7 days. The peak is
higher for 24 hr injection than for 2 hr, but is lower after 7 days. Sample 1 concentration was lowest at 2 hrs and increased progressively with time. (B)
Calculated ratio between sample 3 and sample 1 for individual animals in the study. The fitted regression line suggests that uniform distribution of dextran
along ST (3:1 ratio of 1) would typically take about 11 days to achieve. Also shown on the curve is the change of 3:1 ratio with time initially predicted by
simulations of the experiment.
https://doi.org/10.1371/journal.pone.0183374.g006
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time 30 min; keeping concentrations there low) transitioning to a slower rate at the base (half
time 800 min, allowing concentrations there to become higher). Longitudinal flow was set
to be 0.06 μL/min at the base (causing dilution of samples originating there), but declining
with distance apically along ST until there was zero flow at the apex. This reduced the apical
distribution of dextran. The slowing flow rate with distance could be thought to represent a
Fig 7. Inability of simulation parameter changes to account for measurements after 24 hrs injection. Upper row (A, B) shows how calculated sample
concentrations would be influenced by varying the elimination rate from ST. Concentrations of samples 1 and 2 are decreased as elimination is increased,
indicating a greater gradient along ST. However, in order to achieve the measured ratio between samples 3 and 1 (B), elimination must be so fast that the
dextran concentrations of all samples are reduced well below what is measured (A). Lower row (C,D) shows how calculated sample concentrations are
influenced by varying volume flow along ST. Positive flow rates indicate flow towards the apex along ST and negative rate indicate flow towards the base.
As CSF entry and resulting apically directed perilymph flow along ST was reduced, sample 3:1 ratio increased (D). As basally-directed flow increases
(increasing negative values), the 3:1 ratio approaches the measured value. However, basally directed flow also increases the dextran concentration in
samples 4 and 5 originating from the basal turn (C) as there is less dilution caused by CSF entering ST. Changing flow rates cannot therefore produce the
measured 3:1 ratio and the measured curve shape around samples 4 and 5. These calculations show that the measured results cannot be explained by
adjustments of elimination rate or flow rate in the ear.
https://doi.org/10.1371/journal.pone.0183374.g007
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progressive loss of fluid to some other compartment, such as the vasculature, endolymph, or
middle ear through canaliculi in the bony otic capsule. With these gradients included in the
simulations, curves close to the measured distribution at 2 hrs and 24 hours could be achieved
with the same set of parameters (Fig 8). Simulations with these parameters provide a reason-
able representation of dextran levels over time when dextran solution is delivered to the basal
turn from an implanted cannula.
Implantation-induced changes in auditory function
Changes in auditory sensitivity as a result of implantation, assessed by CAP thresholds and
acoustic emission thresholds are summarized in Fig 9A and 9B respectively. For all implanted
groups, loss of CAP sensitivity was most pronounced at around 6.7 kHz where the mean loss
was close to 30 dB. CAP thresholds of all implanted groups were significantly elevated com-
pared to unimplanted animals over the range of 4 kHz to 11.3 kHz. (ANOVA, Bonferroni t-
tests, p<0.05). Thresholds measured immediately after implantation were significantly ele-
vated across a broader frequency range (ANOVA Bonferroni t-tests, p<0.05, all frequencies
except 1.68 kHz to 2.38 kHz). Acoustic emission thresholds were significantly elevated for 1
day and 7 day groups for frequencies of 4 kHz and higher with significance extending down to
2.8 kHz for the 1 day and 7 day non-injected groups (ANOVA Bonferroni t-tests, p<0.05). Ele-
vation of emission thresholds reached 25 dB at the highest frequencies tested.
The frequency range of CAP threshold measurements and the location of the cochlear implant
are compared on a frequency–place map for the guinea pig (from [32]) in Fig 9C. Frequency vs.
distance along the basilar membrane is shown as the green line, transformed to distances along
ST in the blue line. The implant was inserted about 1.5 mm from the base of ST and extended
6.25 mm up the scala, as indicated by the brown lines. Red lines show the range of significant
CAP threshold elevation, which corresponds to the middle region of the cochlear implant.
Fig 8. Measurements compared to simulations of the experiments. Open symbols: Calculated sample
curves for 2 hr (green) and 24 hr (purple) injections using the same pharmacokinetic parameters. In these
simulations we implemented a base-apex gradient of elimination (800 min half time at the base, transitioning
to 30 min half time at the apex) and a base-apex gradient of volume flow (0.06 μL entering at the base,
transitioning to zero at the apex). This scenario permitted the gradients along ST shown by samples 1–3 to be
approximated after 2hr and 24 hr injections. Solid symbols: Measured group average curves. In the case of 24
hr injections the measured curve is also shown excluding one animal that had an abnormal decline in the later
samples, which largely accounted for the difference between the measured and calculated curves in samples
6–10. The group mean for 7 day injections is also shown, but the calculated curve for 7 days of injection was
identical to that at 24 hours (purple, open symbols) so it has been omitted.
https://doi.org/10.1371/journal.pone.0183374.g008
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Morphologic studies
After fluids sampling and electrophysiological measurements, the ears of animals undergoing
1 day or 7day injections with the implant still in place were fixed for histologic study. In Fig
10A the location of the electrode in ST is seen after SV and the organ of Corti had been dis-
sected away. There is some reddening of the lateral portion of ST (arrow) near the location of
electrodes 4 and 5 (electrodes 2 to 6 are visible in this image). The location of the cannula out-
let is visible just apical to electrode 2. In Fig 10B to 10F the ear was embedded in epoxy resin,
the surface ground and stained with eosin and toluidine blue. In Fig 10B the implant is seen to
be in contact with the spiral prominence near the medial side of the basilar membrane. Fig
10C shows a 7-day specimen with the implant visible in ST and the endolymphatic space visi-
ble. Reissner’s membrane appears normal (arrow) with no indication of endolymphatic
hydrops. In Fig 10D the specimen was ground parallel to the implant allowing the cochleost-
omy, implant and cannula to be visualized. The electrode is seen to be tightly seated in the
cochleostomy. The cannula outlet is clear with no occlusion. In Fig 10E a 24 hr injected speci-
men has been ground orthogonal to the implant. The yellow tip of the cannula is visible, show-
ing no indication of occlusion. At this location, the implant is near the center of ST and does
not contact the sensory organ. Particulate material is present in ST around the implant. Fig
10F shows another 24 hr specimen with particulate matter in the perilymphatic space sur-
rounding the implant.
Discussion
These are the first studies in which the distribution of a substance along ST has been demon-
strated during injection through a cannula incorporated into a cochlear implant. The peri-
lymph measurements found that after 2 hr injections, large concentration gradients were
present along ST. Contrary to our expectations based on prior pharmacokinetic data, the gra-
dients remained and were still substantial, though reduced, after injections of 1 day duration.
They had almost disappeared after injections for 7 days. Based on a fitted line to the sample 3:1
ratio data, it was estimated that an average of 11 days of injection would be required for the
Fig 9. Functional changes caused by implantation. Mean CAP threshold curves (A) and acoustic emission threshold curves (B) for 5 experimental
groups with group numbers given below for CAP and emissions respectively. Unimplanted: (Green: 16, 7); Immediately after implantation (Brown: 9, 1); 1
day after implantation with injection (Purple, 5, 5); 7 days after implantation where injection failed (Blue, 4, 4); 7 days after implantation where injection was
successful (Dark Blue, 3, 3). The implant location is shown on a frequency/distance plot for the guinea pig (C), adapted to show the relationship with
distance along scala tympani (blue curve). The frequency range for significant CAP sensitivity loss corresponds to the middle region of the implant.
https://doi.org/10.1371/journal.pone.0183374.g009
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gradients to disappear. As the FITC-dextran molecule (4000 FW) is relatively large and in
prior studies did not readily pass through cochlear boundaries, longitudinal gradients after
prolonged periods of injection would not be expected for this type of molecule. Gradients are
typically larger and more persistent for smaller molecules that permeate cochlear boundaries
more readily.
Quantitative interpretation of the sustained longitudinal gradients by the simple physical
processes that our simulation program is based on proved to be extremely difficult. In order to
maintain a low concentration for the apical half of ST (from which sample 1 originates) we
considered incorporating a progressively diminishing flow rate along ST (limiting how much
dextran was carried apicalwards) and a gradient of elimination, in which elimination occurred
rapidly from perilymph in apical regions. Although the simulations with these parameters pro-
vided a good representation of the perilymph measurements for injections of up to 24 hours
duration, we have serious concerns about the validity of the solution. A high rate of elimina-
tion from the apex, needed to account for the results of injection from an implant, is not con-
sistent with the findings from prior studies in which dextran was delivered from glass pipettes
sealed into the bony walls of the scalae [30]. In those studies, dextran was lost rapidly from
basal regions of ST, due perilymph-CSF interactions, but was retained well in apical regions of
the cochlea over a 2-hour period. There are a number of possible explanations for the differ-
ence in observations. In prior short-term studies, dextran was injected from a syringe/pipette
system with noncompliant rigid walls, while in the current experiments the implant cannula
was connected to the pump with mechanically compliant silicone tubing. The increased com-
pliance may allow greater respiratory pressure-induced fluid oscillation across the cochlear
aqueduct, perhaps impacting perilymph kinetics. This explanation is thought unlikely as the
Fig 10. Histological assessments of implanted cochleae. (A) 7 day; dissection opening scala vestibuli and removing the organ of Corti. Reddening on the
wall of ST is apparent (arrow). (B) 7 day; implant contacting spiral prominence near basilar membrane (arrow). (C) 7 day; Reissner’s membrane normal
(arrow), no indication of endolyphatic hydrops. (D) 24 hr; tight cochleostomy and unobstructed cannula outlet (arrow). (E) 24 hr; electrode at the region of
cannula outlet near the middle of ST. Some particulate material is present in the fluid space of ST. (F) 24 hr; another specimen with plume of particulate
material in the fluid of ST.
https://doi.org/10.1371/journal.pone.0183374.g010
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greatest influence would have been in the basal turn, rather than the apex. Alternatively, over
the time period of days in this study, the immune response of the ear to the implant could be
influencing perilymph kinetics. All the simulations presented here have assumed parameters
remain constant over time. In mice injected with lipopolysaccharide as a model of sepsis, the
immune response has been shown to degrade the integrity of the blood-labyrinth barrier [33].
In our analysis, increasing permeability of the barrier over time would increase elimination
and potentially explain the persistent gradients for dextran along ST. While this explanation is
an attractive hypothesis, more data are required in support of it. Nevertheless, an implant-
induced compromise of the blood-labyrinth barrier may explain why extended used of sys-
temic steroids was found to help preserve hearing [22]. This could be accounted for if a com-
promised blood-labyrinth barrier gives systemic steroids have greater access to perilymph of
the implanted ear compared to unimplanted ears. Thus, while the simulation parameters
derived from our analysis still provides a quantitative representation of perilymph marker lev-
els with time for up to 24 hours, more complex explanations appear likely. To date, we have
not attempted simulations with time varying parameters but realize this may be required if the
concept becomes better supported by additional data.
We found that fluid leakage at the cochleostomy site had a large influence on the perilymph
levels of dextran achieved. With injections at 100 nL/min, the peak sample concentration
moved from sample 4 (without leakage) to sample 3 when leakage was present. This is due to
the increased washout from the basal turn caused by CSF entry through the cochlear aqueduct
when leakage is present, decreasing the concentration in samples originating from the basal
region of ST. Although this presents a significant problem for animal experiments, the influ-
ence of fluid leakage at the cochleostomy will be far less in humans. CSF pressure in the
human at the level of the cochlear aqueduct is typically negative while sitting or standing. The
cochlear aqueduct is longer and narrower in humans compared to rodents [34] and ST volume
is larger in the humans, so the influence of volume influx on ST kinetics will be lower. If effi-
cacy and toxicity are established in animals as the dose is varied, both may be underestimated
compared to the human as the drug washout present in animals with leaking cochleostomies
will not occur to the same degree in humans with leaking cochleostomies.
Placement of an implant in a normally-hearing ear resulted in a hearing loss for frequencies
from 4 to 11.3 kHz which averaged as high as 30 dB. Lower and higher frequency responses
were less affected or not significantly affected. The hearing loss was stable over the 7-day dura-
tion of this study. The absence of a time course of change (such as a progressive deterioration
or progressive improvement with time), suggests it does not arise from gross damage to the
organ of Corti or spiral ligament, or from mechanical overstimulation during implantation,
comparable to noise exposure. Instead, the loss is more compatible with a restriction of basilar
membrane motion, perhaps by contact with the implant, or with local disturbance of some
other aspect of transduction, such as the electrically insulating silicone disturbing normal cur-
rent or ion flow in the fluids. The similarity of acoustic emission and CAP changes supports
the idea that function of the outer hair cells is being impeded in some manner. Although we
did not quantify endolymphatic changes in this study we saw no evidence of endolymphatic
hydrops in histologic specimens (Fig 10) and no indication of low frequency hearing loss (Fig
9). This differs from the report of Smeds et al. [13] that suggested endolymphatic hydrops was
prevalent in the first weeks following implantation. The magnitude of the losses found here are
comparable to the 20–30 dB losses reported previously based on ABR and CAP recordings in
implanted guinea pigs with initially normal hearing [1,2,35,36]. However, contrary to the prior
studies we found threshold elevations to be limited to the implant location with no significant
influence on high and low frequency responses. The functional changes measured here were
limited to the initial 7-day period after implantation in normally-hearing animals with no
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electrical stimulation and therefore have limited relevance to the progressive changes occur-
ring over much longer time courses with ongoing electrical stimulation. Nevertheless, studying
the origins, mechanisms and progression of hearing loss in the implanted ear will provide a
better understanding of implantation-induced hearing loss.
Histologic analysis using a technique that allowed the electrode to remain in place showed
there was no indication of occlusion at the cannula outlet. This is probably because injection
occurred continuously throughout the study period. In specimens injected for 24 hrs we
observed a plume of particulate material in the fluid space of ST associated with the implant.
The resolution of the histologic technique used here did not allow the nature of these particles,
cellular or otherwise, to be identified. Others have reported foreign body giant cells, macro-
phages and lymphocytes associated with the implant when examined years [37], 4 weeks [38]
or 3 days [39] after implantation. Our observations suggest a strong morphologic response to
implantation can occur within 24 hours of the procedure. It is probable that the response in
the perilymphatic space of ST would not be resolved if the implant was removed prior to
processing.
All experiments in this study used a large (4000 MW) dextran marker which does not read-
ily pass through cell membranes and is retained in perilymph better than all other substances
tested to date [30]. The low rate of elimination acts to minimize longitudinal gradients along
the scala. If a substance is eliminated from perilymph more rapidly, gradients are larger and
may be maintained longer over time. An example is dexamethasone which is eliminated from
ST with a half-time of 22 min [40]. When applied locally to the base of the cochlea, dexametha-
sone is lost rapidly as it diffuses along the scala to an extent where a steady state is established
and where it never reaches the apex in appreciable concentrations. We therefore expect that if
gradients for dextran are present along the scala, then even larger gradients would be present
for other substances that are eliminated more rapidly than dextran.
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